Healthy
Conditions
Brief summary
The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening.
Interventions
DRUGLY3866288
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Females must be of nonchildbearing potential or of childbearing potential and agree to use contraception * Males must either be infertile via bilateral orchiectomy or vasectomized at least 90 days prior to screening with proper documentation * Body mass index (BMI) between 18.5 and 32.0 kilogram per square meter (kg/m²) * In good general health, determined by no clinically significant findings from medical history, physical examination, 12 lead electrocardiogram (ECGs), vital signs measurements, or clinical laboratory evaluations at screening and/or check-in as assessed by the investigator (or designee)
Exclusion criteria
* Females only: Are lactating or pregnant * Any history or presence of disease(s), deemed clinically significant: * Dermatological disease * Liver disease * Metabolic disease, including congenital nonhemolytic hyperbilirubinemia (e.g., Gilbert syndrome) * Gastrointestinal disease, including peptic ulcer disease, active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug, or gastric reduction surgery. Note: participants with a history of appendectomy and/or inguinal hernia repairs will be acceptable * Biliary disease, including cholecystectomy * Cancer within the past 5 years (except localized basal cell, squamous, or in situ cancer of the skin) * History or current evidence of ophthalmic disorder, such as central serous retinopathy or retinal vein occlusion, active wet age-related macular degeneration, diabetic retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration * Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to first dose, or 12-lead ECG abnormalities that are clinically significant at screening * History of alcohol and/or drug abuse within 2 years prior to screening * Have been on a diet incompatible with the on-study diet, in the opinion of the investigator (or designee), and as confirmed by the sponsor, within the 30 days prior to Day 1 and throughout * Use of tobacco, smoking cessation products, products containing nicotine, or e-cigarettes (nicotine and non-nicotine) within 90 days prior to screening and throughout
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK: Maximum Concentration (Cmax) of LY3866288 | Baseline to Study Completion (Up to 3 Weeks) | PK: Cmax of LY3866288 |
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288 | Baseline to Study Completion (Up to 3 Weeks) | PK: AUC From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288 |
| PK: AUC Extrapolated to Infinity of LY3866288 | Baseline to Study Completion (Up to 3 Weeks) | PK: AUC Extrapolated to Infinity of LY3866288 |
Countries
United States
Outcome results
None listed